Loading organizations...

Encoded Therapeutics is a technology company.
Encoded Therapeutics develops genetic medicines designed to address the underlying causes of severe neurological disorders. The company leverages its proprietary genomics-based platform to create gene therapies, focusing on treatments that offer potentially long-lasting and impactful benefits for patients. This scientific approach targets both monogenic and more common neurological conditions, aiming to modulate gene expression with precision.
The company was co-founded in 2014 by Kartik Ramamoorthi and Stephanie Tagliatela. Their foundational insight involved establishing a genomics-based platform technology to unlock new therapeutic avenues for complex neurological diseases. This endeavor stemmed from a commitment to translating advanced scientific understanding into practical, patient-focused interventions.
Encoded Therapeutics aims to deliver transformative therapies to individuals living with neurological disorders. The company’s long-term vision centers on fostering a culture of relentless patient focus, creativity, and scientific exploration to redefine treatment paradigms for these challenging conditions, ultimately improving patient outcomes through innovative genetic medicines.
Encoded Therapeutics has raised $240.0M across 2 funding rounds.
Encoded Therapeutics has raised $240.0M in total across 2 funding rounds.
Encoded Therapeutics is a biotechnology company developing precision gene therapies for severe genetic disorders, particularly neurological conditions like Dravet syndrome, using a novel platform that enhances cell-type selectivity, potency, and gene expression control via genomics and computational technologies.[1][2][4] Its lead candidate, ETX101, targets Dravet syndrome by upregulating endogenous SCN1A expression in relevant cell types, addressing limitations of first-generation gene therapies; the company serves patients with neurocircuitry disorders, liver/metabolic diseases, neurodegeneration, and cardiovascular conditions, solving unmet needs in disorders untreatable by current approaches.[2][3][4] Encoded raised $104 million in Series C financing in 2022 to advance ETX101 into clinical development and expand its preclinical pipeline, demonstrating strong growth momentum through investor support from firms like Venrock and ARCH Venture Partners, incubated by Illumina Accelerator.[2][4]
Encoded Therapeutics was incubated by the Illumina Accelerator and seeded by Venrock and ARCH Venture Partners, with co-founder and CEO Kartik Ramamoorthi, Ph.D., leading the vision to translate genomics-driven insights into gene therapies.[4] The idea emerged from identifying key limitations in existing viral gene therapies—such as poor cell selectivity and inefficient gene delivery—prompting the development of a platform using regulatory elements from the human genome, optimized via computational tools and packaged into AAV vectors to mimic natural gene expression patterns.[1][2][4] Early traction included preclinical data for Dravet syndrome presented at the 2022 American Society of Gene & Cell Therapy meeting, showcasing cell-selective targeting and upregulation, followed by the $104 million Series C raise to propel programs forward.[2][4]
Encoded rides the wave of next-generation gene therapy advancements, fueled by genomics progress and computational biology, timing perfectly with rising demand for precise, durable treatments amid limitations of early AAV therapies.[1][2][4] Market forces like increasing rare disease awareness, regulatory nods for gene therapies (e.g., FDA-approved AAVs), and investor enthusiasm for biotech platforms favor Encoded's approach, which unlocks previously untreatable disorders through enhanced selectivity and potency.[2][3][4] By focusing on pediatric CNS disorders like Dravet syndrome and partnering with patient advocacy groups, Encoded influences the ecosystem by accelerating clinical translation, fostering community-driven development, and setting standards for genomics-integrated precision medicine.[3][5]
Encoded is poised to advance ETX101 through clinical trials, leveraging its Series C funds to build a fully integrated therapeutics company with multiple preclinical assets across high-need areas.[2][4] Trends like AI-enhanced genomics design, expanded AAV manufacturing, and regulatory pathways for rare epilepsies will shape its trajectory, potentially yielding first-in-class approvals that redefine disease modification over symptom management.[1][3] Its influence may evolve from platform innovator to ecosystem leader, inspiring similar biotech ventures and amplifying patient voices in therapy design—translating next-generation science into transformative realities for genetic disorders.[1][6]
Encoded Therapeutics has raised $240.0M in total across 2 funding rounds.
Encoded Therapeutics's investors include GV, Menlo Ventures, Anne Wojcicki, ARCH Venture Partners, Boxer Capital, Farallon Capital Management, HBM Genomics, Illumina Ventures, Matrix Capital Management, Meritech Capital Partners, Nolan Capital, Perceptive Advisors.
Encoded Therapeutics has raised $240.0M across 2 funding rounds. Most recently, it raised $140.0M Series D in July 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2020 | $140.0M Series D | GV | Menlo Ventures, Anne Wojcicki, ARCH Venture Partners, Boxer Capital, Farallon Capital Management, HBM Genomics, Illumina Ventures, Matrix Capital Management, Menlo Ventures, Meritech Capital Partners, Nolan Capital, Perceptive Advisors, RTW Investments, SoftBank |
| Jun 1, 2019 | $100.0M Series C | Menlo Ventures, Alexandria Venture Investments, Altitude Life Science Ventures, Robert Nelsen, Boxer Capital, Illumina Ventures, Karan Takhar, Menlo Ventures, RTW Investments, Bryan Roberts |